Xie Meng, Dart Dafydd Alwyn, Owen Sioned, Wen Xianzi, Ji Jiafu, Jiang Wenguo
Department of Gastrointestinal Translational Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Haidian, Beijing 100142, P.R. China.
Cardiff China Medical Research Collaborative, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK.
Oncol Rep. 2016 Sep;36(3):1191-8. doi: 10.3892/or.2016.4908. Epub 2016 Jun 27.
Gastric cancer (GC) remains the third most common cause of cancer deaths worldwide and carries a high rate of metastatic risk contributing to the main cause of treatment failure. An accumulation of data has resulted in a better understanding of the molecular network of GC, however, gaps still exist between the unique bio-resources and clinical application. MicroRNAs are an important part of non-coding RNAs and behave as major regulators of tumour biology, alongside their well-known roles as intrinsic factors of gene expression in cellular processes, via their post-transcriptional regulation of components of signalling pathways in a coordinated manner. Deregulation of the miR-1, -133 and -206 family plays a key role in tumorigenesis, progression, invasion and metastasis. This review aims to provide a summary of recent findings on the miR-1, -133 and -206 family in GC and how this knowledge might be exploited for the development of future miRNA-based therapies for the treatment of GC.
胃癌（GC）仍是全球癌症死亡的第三大常见原因，且转移风险率很高，这是导致治疗失败的主要原因。大量数据积累使人们对胃癌的分子网络有了更好的了解，然而，独特的生物资源与临床应用之间仍存在差距。微小RNA是非编码RNA的重要组成部分，除了在细胞过程中作为基因表达的内在因子发挥众所周知的作用外，还通过对信号通路成分的转录后调控，协同作为肿瘤生物学的主要调节因子。miR-1、-133和-206家族的失调在肿瘤发生、进展、侵袭和转移中起关键作用。本综述旨在总结GC中miR-1、-133和-206家族的最新研究发现，以及如何利用这些知识开发未来基于miRNA的GC治疗方法。
